VYNE - VYNE Therapeutics rises 8% on positive data from Phase 1 trial of vitiligo treatment

• VYNE Therapeutics ( NASDAQ: VYNE ) is trading ~8% higher premarket after it announced positivedata from the Phase 1 trial testing novel BET inhibitor, VYN201, for vitiligo.
• The early-stage trial tested single ascending and multiple ascending doses of VYN201, which were applied topically once daily to 30 volunteers in five dose cohorts for two weeks with a one-week safety follow-up.
• The company had selected 0.5%, 1% and 2% ointment strengths for evaluation in the ongoing Phase 1b study in non-segmental vitiligo patients.
• Vitiligo is a chronic autoimmune depigmenting disorder of the skin, characterized by the loss of pigment producing cells known as melanocytes.
• Press Release

For further details see: